We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · September 11, 2021

Teprotumumab Early Response Is Not Required for Benefit for Thyroid Eye Disease

Eye (London, England)


Additional Info

Eye (London, England)
Teprotumumab for Thyroid Eye Disease: Early Response Is Not Required for Benefit
Eye (Lond) 2021 Jun 28;[EPub Ahead of Print], S Ugradar, Y Wang, T Mester, GJ Kahaly, RS Douglas

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading